Ant Group’s ESG strategy aims to support 100 million SMEs by 2030
Ant Group, a global technology provider, today announced its Environmental, Social and Governance (ESG) strategy as part of its latest sustainability report. The ESG strategy, which lays out Ant Group’s sustainable development objectives by 2030, will be implemented across all aspects of the Company’s operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531006112/en/
Four pillars of Ant Group’s ESG strategy and objectives by 2030 (Graphic: Business Wire)
Ant Group’s ESG strategy is focused around four pillars: Digital Inclusion, Green and Low-carbon Development, Open Ecosystem, and Technological Innovation. Each of the pillars has a corresponding sustainable development objective by 2030:
- Digital Inclusion: support 100 million small and micro-sized enterprises (SMEs) and serve communities globally
- Green and Low-carbon Development: achieve corporate carbon neutrality and support business partners and the general public to significantly reduce their carbon footprint
- Open Ecosystem: continue to provide a safe, trusted, diversified and open ecosystem to drive common development with partners
- Technological Innovation: continue to invest in core technology research and development to provide world-leading technological products and services
"We believe these are the most important pillars for Ant Group to achieve sustainable growth in a future-facing, responsible, and responsive manner,” wrote Eric Jing, Ant Group’s Chairman and CEO, in the sustainability report. ”This framework will guide Ant Group’s value creation and sustainable development in the future.”
Ant Group formulated its ESG strategy based on a comprehensive assessment of changing macro environment and policy trends, its own development strengths, and inputs from the Company’s stakeholders, including customers, users, employees, partners and governments. The ESG strategy was finalized after extensive management discussions and a detailed Board review.
After solicitating feedback from stakeholders, Ant Group defined 19 material issues for its ESG strategy, ranging from “responsible products and services,” “facilitating industry-wide carbon neutrality,” “cutting-edge technology discovery and R&D” and “transparency & risk management.”
To provide organizational support to effectively implement the ESG strategy, the Company’s Board of Directors has approved the establishment of an ESG sustainable development committee, comprised of a subset of the Board, responsible for decision-making supervision, risk management and policy making. The Company is setting up an advisory committee consisting of internal and external ESG experts to provide input and support. Ant Group has also set up an ESG sustainable development leadership team, led by the CEO and the Chief Sustainability Officer, as well as working groups for each of the 19 ESG material issues.
“Our ESG strategy originated from our own long-term needs and was not a spur-of-the-moment decision. The pursuit of sustainable development has been inherent in every step of our journey and is not designed to cater to short-term trends, but rather a necessary driver to realize our vision to be a good company that will last for at least 102 years,” added Mr. Jing. “A good company is never independently defined. We will listen to the opinions and suggestions from all parties with an open mind and welcome supervision and guidance from all of our stakeholders.”
As part of its “Technological Innovation” pillar, Ant Group has been increasing its R&D investments, which grew at an annual rate of more than 39% for three consecutive years (2018-2021), with total R&D spending in 2021 exceeding RMB 18.8 billion (approx. USD 2.77 billion). These investments enabled the Company to continuously turn technological breakthroughs into innovative, inclusive and reliable products and services to support the digital transformation of industries and better anticipate the evolving needs of an increasingly digital global economy. In 2021, MYbank, an Ant Group associate and an online SME bank, leveraged digital technology to deliver convenient, accessible and responsible collateral-free financing services to 45 million SMEs.
In February 2022, Ant Group was recognized as a Top 100 Global Innovator™ 2022 by Clarivate™. This prestigious annual list identifies global companies and institutions that contribute new ideas, solve problems and create new economic value.
Since 2017, three years after Ant Group’s establishment, the Company has steadily introduced and advanced its ESG assessment framework and published an annual sustainability report, compiled according to the Global Reporting Initiative standards. These reports, including the latest 2021 edition with the Company’s ESG strategy, can be found on Ant Group’s website (Chinese only for now, English edition will be online in the coming weeks).
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006112/en/
Contact information
Media Inquiries
Le SHEN
Shenle.sl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom